Radiation Therapy for Hepatocellular Carcinoma

Seminars in Radiation Oncology

Volumn 21, Issue 4, 2011, Pages 271-277

  Feng, Mary ^a   Ben Josef, Edgar ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLOXURIDINE; SORAFENIB;

CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; RADIOSURGERY; RADIOTHERAPY, CONFORMAL;

EID: 80053041611     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.05.002     Document Type: Review

References (52)

1. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. El-Serag H.B. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
3. Braga L., Guller U., Semelka R.C. Modern hepatic imaging. Surg Clin North Am 2004, 84:375-400.
4. Marrero J.A., Hussain H.K., Nghiem H.V., et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplant 2005, 11:281-289.
5. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67.
6. Bruix J., Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-524.
7. Jonas S., Bechstein W.O., Steinmuller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
8. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
9. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
10. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359:1734-1739.
11. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
12. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
13. Robertson J.M., McGinn C.J., Walker S., et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 1997, 39:1087-1092.
14. McGinn C.J., Ten Haken R.K., Ensminger W.D., et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998, 16:2246-2252.
15. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
16. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747.
17. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53:810-821.
18. Mornex F., Girard N., Beziat C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-Mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66:1152-1158.
19. Thomas E., Chapet O., Kessler M.L. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys 2005, 62:571-578.
20. Seong J., Lee I.J., Shim S.J., et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009, 29:147-152.
21. Liang S.X., Zhu X.D., Lu H.J., et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005, 103:2181-2188.
22. Liu M.T., Li S.H., Chu T.C., et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004, 34:532-539.
23. Huang Y.J., Hsu H.C., Wang C.Y., et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 73:1155-1163.
24. Toya R., Murakami R., Baba Y., et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007, 84:266-271.
25. Blomgren H., Lax I., Naslund I., et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
26. Mendez-Romero A., Wunderink W., Hussain S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol 2006, 45:831-837.
27. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
28. Cardenes H.R., Price T.R., Perkins S.M., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.
29. Kwon J.H., Bae S.H., Kim J.Y., et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10:475.
30. Seo Y.S., Kim M.S., Yoo S.Y., et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010, 102:209-214.
31. Louis C., Dewas S., Mirabel X., et al. Stereotactic radiotherapy of hepatocellular carcinoma: Preliminary results. Technol Cancer Res Treat 2010, 9:479-487.
32. Liang S.X., Zhu X.D., Xu Z.Y., et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006, 65:426-434.
33. Liang S.X., Huang X.B., Zhu X.D., et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh grade A cirrhosis. Radiother Oncol 2010, 98:265.
34. Son S.H., Choi B.O., Ryu M.R., et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: Dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010, 78:1073-1080.
35. Andolino D.L., Forquer J.A., Henderson M.A., et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011, 80:692-697.
36. Stephans K.L., Djemil T., Tendulkar R.D., et al. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 2011, [Epub ahead of print].
37. Chiba T., Tokuuye K., Matsuzaki Y., et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005, 11:3799-3805.
38. Zhou Z.H., Liu L.M., Chen W.W., et al. Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 2007, 80:194-201.
39. Seong J., Park H.C., Han K.H., et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003, 55:329-336.
40. Zeng Z.C., Tang Z.Y., Fan J., et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004, 10:307-316.
41. Li B., Yu J., Wang L., et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol 2003, 26:e92-e99.
42. Guo W.J., Yu E.X., Liu L.M., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003, 9:1697-1701.
43. Cheng J.C., Chuang V.P., Cheng S.H., et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000, 47:435-442.
44. Koo J.E., Kim J.H., Lim Y.S., et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2010, 78:180-187.
45. Shim S.J., Seong J., Han K.H., et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005, 25:1189-1196.
46. Meng M.B., Cui Y.L., Lu Y., et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiother Oncol 2009, 92:184-194.
47. Wang G., Shen W., Song M., et al. Results of combined treatment with transcatheter hepatic arterial chemoembolization and whole-liver irradiation with the moving strip technique in unresectable hepatocellular carcinoma. Int J Clin Oncol 2000, 5:380-385.
48. McIntosh A., Hagspiel K.D., Al-Osaimi A.M., et al. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009, 115:5117-5125.
49. Kim T.H., Kim D.Y., Park J.W., et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006, 29:568-575.
50. Oh K.S., Soto D.E., Smith D.C., et al. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: Long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2009, 74:511-517.
51. Goyal K., Einstein D., Yao M., et al. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: Preliminary results. HPB Surg 2010, 309780.
52. Stenmark M.H., Liu E., Schipper M.J., et al. SBRT outcomes for primary and metastatic liver lesions. Gastrointestinal Cancers Symposium January 20-22, 2011.